急性完全性脊髓损伤髓内注射骨髓间充质干细胞的安全性与可行性:1期试验
这项前瞻性研究在2年内将27例急性完全性脊髓损伤患者随机分配至术中椎管减压融合时髓内注射骨髓间充质干细胞或安慰剂,评估安全性与可行性;最终13例完成分析(干细胞组7例、对照组6例),未观察到与干细胞注射相关的不良事件,作者认为髓内注射骨髓间充质干细胞安全可行。
要点
- 急性完全性脊髓损伤患者术中髓内注射骨髓间充质干细胞,未发现与注射相关的不良事件。
- 研究共筛查180例,入组27例,最终13例完成分析(干细胞组7例、对照组6例)。
- 对照组5例、干细胞组3例在随访期间死亡。
核心结论
- 作者认为,髓内注射骨髓间充质干细胞用于急性完全性脊髓损伤患者是安全且可行的。
研究设计与样本
- 前瞻性研究,为期2年,将27例急性(定义为伤后1周内)完全性脊髓损伤患者随机分配至术中椎管减压融合时髓内注射骨髓间充质干细胞组或安慰剂组。
- 研究获得机构伦理批准,所有患者均签署知情同意书。
- 安全性通过术前及术后3个月、6个月的实验室和临床影像学参数评估。
主要发现
- 研究期间共筛查180例患者,其中27例入组。
- 3例退出、3例失访、8例死亡,最终13例纳入分析,其中干细胞组7例、对照组6例。
- 两组在性别、年龄和体重方面匹配良好。
- 实验室和影像学参数方面未观察到与干细胞注射相关的不良事件。
- 随访期间对照组5例、干细胞组3例死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The intramedullary route holds the potential to provide the most concentration of stem cells in cases of spinal cord injury (SCI). However, the safety and feasibility of this route need to be studied in human subjects. The aim of this study was to evaluate the safety and feasibility of intramedullary injected bone marrow-derived mesenchymal stem cells (BM-MSCs) in acute complete SCI. METHODS: In this prospective study conducted over a 2-year period, 27 patients with acute (defined as within 1 week of injury) and complete SCI were randomized to receive BM-MSC or placebo through an intramedullary route intraoperatively at the time of spinal decompression and fusion. Institutional ethics approval was obtained, and informed consent was obtained from all patients. Safety was assessed using laboratory and clinicoradiological parameters preoperatively and 3 and 6 months after surgery. RESULTS: A total of 180 patients were screened during the study period. Of these, 27 were enrolled in the study. Three patients withdrew, 3 patients were lost to follow-up, and 8 patients died, leaving a total of 13 patients for final analysis. Seven of these patients were in the stem cell group, and 6 were in the control group. Both groups were well matched in terms of sex, age, and weight. No adverse events related to stem cell injection were noted for laboratory and radiological parameters. Five patients in the control group and 3 patients in the stem cell group died during the follow-up period. CONCLUSIONS: Intramedullary injection of BM-MSCs was found to be safe and feasible for use in patients with acute complete SCI.
引用
- Saini R, Pahwa B, Agrawal D, et al. Safety and feasibility of intramedullary injected bone marrow-derived mesenchymal stem cells in acute complete spinal cord injury: phase 1 trial. J Neurosurg Spine. 2022. PMID: 35395638. doi:10.3171/2022.2.SPINE211021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。